FY2025 · ended Dec 31, 2025 · Revenue $88.50M, +24.1% YoY · Filed Feb 26, 2026
Biodesix, Inc. (BDSX) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $88.5 million and a net loss of $35.3 million. Free cash flow was -$23.5 million. As of Sep 30, 2026 it held $28.4 million in cash and investments and $75.3 million in total debt.
Revenue (TTM)
$105.21M
+31.2% vs year-ago TTM
Net income (TTM)
$-27.08M
+31.5% vs year-ago TTM
Operating cash flow (TTM)
$-18.16M
+35.5% vs year-ago TTM
Free cash flow (TTM)
$-19.07M
+34.6% vs year-ago TTM
EPS (TTM)
$-2.80
+47.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
9.86M
-93.2% vs prior year
Net cash
$-46.88M
as of Sep 30, 2026
Operating margin
-18.7%
FY 2026
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- BDSX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Louisville, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1439725
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $88.5M | $71.3M | $49.1M | $38.2M | $54.5M |
| Operating income | -$27.9M | -$34.5M | -$41.3M | -$50.6M | -$40.9M |
| Net income | -$35.3M | -$42.9M | -$52.1M | -$65.4M | -$43.2M |
| Diluted EPS | -$4.67 | -$6.64 | -$0.64 | -$1.55 | — |
| Operating cash flow | -$23.3M | -$48.6M | -$22.9M | -$45.0M | -$28.2M |
| Free cash flow | -$23.5M | -$51.9M | -$45.8M | -$48.3M | -$30.5M |
| Total assets | $87.5M | $97.2M | $99.1M | $92.9M | $76.1M |
| Total liabilities | $89.9M | $76.4M | $94.5M | $72.3M | $56.4M |
| Stockholders' equity | -$2.5M | $20.9M | $4.6M | $20.6M | $19.7M |
| Cash and investments | $19.0M | $26.2M | $26.3M | $43.1M | $32.7M |
| Total debt | $75.4M | $65.6M | $65.5M | $36.9M | $11.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 20, 2026 | May 19, 2026 |
| 10-Q | Quarterly report | May 4, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 4, 2026 | May 4, 2026 |
| ARS | Annual report to shareholders | Apr 9, 2026 | Dec 31, 2025 |
All 597 Biodesix, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.